| 注册
首页|期刊导航|山东医药|帕金森及肌张力障碍患者丘脑底核脑深部电刺激术中的治疗靶点定位

帕金森及肌张力障碍患者丘脑底核脑深部电刺激术中的治疗靶点定位

张华 石林 杨岸超 朱冠宇 陈颍川 张建国

山东医药2017,Vol.57Issue(11):7-10,4.
山东医药2017,Vol.57Issue(11):7-10,4.DOI:10.3969/j.issn.1002-266X.2017.11.003

帕金森及肌张力障碍患者丘脑底核脑深部电刺激术中的治疗靶点定位

Subthalamic nuclei targeting in deep brain stimulation surgeries in patients with Parkinson's disease and dystonia

张华 1石林 1杨岸超 1朱冠宇 1陈颍川 1张建国2

作者信息

  • 1. 首都医科大学附属北京天坛医院,北京100050
  • 2. 北京市神经外科研究所
  • 折叠

摘要

Abstract

Objective To explore the feasibility of subthalamic nuclei (STN) targeting by magnetic resonance imaging (MRI) and intraoperative microelectrode recording before deep brain stimulation (DBS) in patients with Parkinson's disease and dystonia.Methods We selected 202 patients (382 sides) undergoing STN-DBS for Parkinson's and dystonia.STN sites targeted by MRI were testified by intraoperative microelectrode recording after opening cranium before DBS.Results ① STN targeted by MRI were clearly manifested in 288 of 382 sides, were ordinarily manifested in 72 sides and blurred in 22 sides.② The STN signals harvested in all 382 sides.The number of trajectories required to obtain sufficient STN activity was one in 339 sides, two in 43 sides.The STN signals were typical in 356 in 382 sides (93.1%) and untypical in 26 sides (6.9%).The mean STN length was (5.9±1.1) mm.③ 341 sides (94.7%) received typical STN signals in 360 satisfactory STN-targeting sides (clearly and ordinarily), as 15 sides (68.2%) received typical STN signals in 22 unsatisfactory STN-targeting sides before DBS.Conclusion MRI and intraoperative microelectrode recording can target subthalamic nuclei (STN) accurately before DBS in patients with Parkinson's disease and dystonia.

关键词

脑深部电刺激/丘脑底核/帕金森病/肌张力障碍/磁共振成像/电生理检测

Key words

deep brain stimulation/subthalamic nuclei/Parkinson's disease/dystonia/magnetic resonance imaging/microelectrode recording

分类

医药卫生

引用本文复制引用

张华,石林,杨岸超,朱冠宇,陈颍川,张建国..帕金森及肌张力障碍患者丘脑底核脑深部电刺激术中的治疗靶点定位[J].山东医药,2017,57(11):7-10,4.

基金项目

国家自然科学基金资助项目(81301183) (81301183)

北京市医管局临床医学发展专项基金(ZYLX201305). (ZYLX201305)

山东医药

OACSTPCD

1002-266X

访问量0
|
下载量0
段落导航相关论文